Enteropathic Arthritis

How to Cite This Chapter: Carmona R, Szechiński J. Enteropathic Arthritis. McMaster Textbook of Internal Medicine. Kraków: Medycyna Praktyczna. https://empendium.com/mcmtextbook/chapter/B31.II.16.12.4 Accessed February 21, 2020.
Last Updated: June 17, 2019
Last Reviewed: June 17, 2019
Chapter Information

Definition, Etiology, PathogenesisTop

Enteropathic arthritis is associated with inflammatory bowel disease (IBD): ulcerative colitis (UC) (see Ulcerative Colitis) and Crohn disease (CD) (see Crohn Disease). Etiology is unknown.

Clinical Features and Natural HistoryTop

Peripheral arthritis is acute, migratory, asymmetric and most frequently involves the knees and ankles. It is generally nonerosive.

Types of peripheral joint involvement:

1) Type 1: Acute oligoarthritis (involvement of ≤5 joints) that may precede gastrointestinal manifestations or occur early in the disease course and is often associated with IBD flares, self-limiting (2-6 months), and frequently accompanied by extraintestinal features (eg, erythema nodosum). It affects 5% to 10% of patients with IBD.

2) Type 2: Polyarthritis (>5 joints) is usually independent of IBD activity, has a chronic course (months or years), and is associated with no extraintestinal features except for uveitis. It affects 3% to 4% of patients with IBD.

Spondyloarthritis with axial involvement: Inflammatory back pain (see Table 15.20-1) is the typical presentation of axial disease, occurring with or without peripheral arthritis. It is usually unrelated to bowel disease activity. From 10% to 20% of patients can develop clinical and radiographic features similar to ankylosing spondylitis (AS). Imaging studies can be negative in early spondyloarthritis. It is important to consider that arthralgia (in the absence of inflammatory arthritis) is very common in IBD, affecting about 10% of patients (as many as 50% in some studies).

Involvement of other organs in the course of IBD: see Ulcerative Colitis; see Crohn Disease.

Natural history: Type 1 peripheral arthritis typically occurs early and is self-limiting (<6 months). Patients with type 2 peripheral arthritis may continue to have recurrent flares for many years. Axial enteropathic arthritis can cause disability and significantly impact quality of life. Peripheral enteropathic arthritis usually causes no permanent joint lesions or deformity.


Diagnostic Tests

1. Laboratory tests: Markers of inflammation (elevated erythrocyte sedimentation rate [ESR]/C-reactive protein [CRP], thrombocytosis, anemia) can be confounded by bowel disease. Rheumatoid factor (RF) is usually negative. HLA-B27 is positive in 50% to 75% of patients with IBD-associated axial arthritis.

2. Synovial fluid examination: Findings are nonspecific and characteristic of inflammatory arthritis.

3. Imaging studies:

1) Radiography: Peripheral enteropathic arthritis is usually nonerosive, with <10% of patients having erosions of the affected joints. Radiographs may show soft-tissue swelling, periarticular osteopenia, and mild periostitis. Radiographic features in axial involvement are similar to AS. Asymptomatic sacroiliitis can occur in up to 20% of patients.

2) Magnetic resonance imaging (MRI): Similarly to AS, MRI can be used to assess for axial disease where radiographs are normal or to exclude inflammatory disease in mechanical back pain (when indicated).

Diagnostic Criteria

1. Diagnosis of UC or CD.

2. Features of peripheral arthritis or axial spondyloarthritis (diagnosis of axial spondyloarthritis often requires confirmation by imaging studies).

Differential Diagnosis

1. Peripheral enteropathic arthritis: Atypical rheumatoid arthritis, infectious arthritis, reactive arthritis, psoriatic arthritis.

2. Spondyloarthritis: Other spondyloarthritides.


Treatment of the Underlying Condition

Many drugs used for IBD itself can benefit the articular manifestations. In addition, type 1 peripheral arthritis usually mirrors IBD disease activity and improves with improvement of the underlying IBD.

Treatment of Joint Involvement

1. Physiotherapy is helpful for the maintenance of functional capacity, particularly in patients with axial enteropathic arthritis.

2. Pharmacotherapy:

1) Use acetaminophen (INN paracetamol)-based products for pain control. Nonsteroidal anti-inflammatory drugs (NSAIDs) are generally avoided because of the potential risk of worsening IBD; however, NSAIDs (cyclooxygenase 1 [COX-1] and 2 [COX-2] inhibitors) can be used for arthritis if IBD is quiescent and in consultation with a gastroenterologist.

2) Sulfasalazine is the first-line disease-modifying antirheumatic drug (DMARD) in patients with peripheral enteropathic arthritis.Evidence 1Strong recommendation (benefits clearly outweigh downsides; right action for all or almost all patients). Low Quality of Evidence (low confidence that we know true effects of the intervention). Quality of Evidence lowered due to indirectness. Olivieri I, Cantini F, Castiglione F, et al. Italian Expert Panel on the management of patients with coexisting spondyloarthritis and inflammatory bowel disease. Autoimmun Rev. 2014 Aug;13(8):822-30. doi: 10.1016/j.autrev.2014.04.003. Epub 2014 Apr 13. Review. PubMed PMID: 24726868. If it is ineffective or not tolerated, consider methotrexate or azathioprine. DMARDs are ineffective in patients with axial spondyloarthritis. Agents, dosage, contraindications, and adverse effects of DMARDs: see Table 15.18-3.

3) Intra-articular glucocorticoids can provide effective short-term relief in monoarthritis or oligoarthritis. Short-term systemic glucocorticoids may provide rapid short-term relief in patients with peripheral enteropathic arthritis.

4) Anti–tumor necrosis factor (TNF) agents (infliximab, adalimumab, golimumab, certolizumab) have beneficial effects on both intestinal manifestations and arthritis (axial and peripheral). Etanercept is ineffective for the treatment of IBD itself.

We would love to hear from you

  • Do you have any comments?
  • Have you found a mistake?
  • Would you like to suggest a feature?

We use cookies to ensure you get the best browsing experience on our website. Refer to our Cookies Information and Privacy Policy for more details.